Renal anemia renal anemia, chronic kidney disease, roxadustat, erythropoietin
Conditions
Interventions
None listed
Sponsors
Hamano Takayuki
Murashima Miho
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Hemodialysis patients age>=20 and 15 years receiving treatment with erythropoiesis stimulating agents (ESA) requiring change from ESA to HIF-PH inhibitors for clinical reasons those who consent to participation to the research Patients with non-dialysis dependent chronic kidney disease age>=20 and <95 receiving treatment with ESA requiring change from ESA to HIF-PH inhibitors for clinical reasons those who consent to participation to the research
Exclusion criteria
Exclusion criteria: Those with malignancy Those with deep venous thrombosis Hematologic malignancy including myelodysplastic syndrome Iron deficiency (transferrin saturation <20% or ferritin <100ng/mL) Active bleeding Liver dysfunction (Child Pugh class B or C) Diabetic proliferative retinopathy Those who were deemed to be ineligible by treating physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of erythropoietin derived from kidneys or liver 1-2 week and 12 weeks after swithing from ESA to roxadustat | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients achieving target hemoglobin of 10-12g/dL 12 weeks after initiation of roxadustat, hemogloin, erythroferron, and hepcidin levels 12 weeks after initiation of roxadustat | — |
Contacts
Public ContactMiho Murashima
Nagoya City University Hospital
Outcome results
None listed